Evidence map›Paper›PMID 41492094›Full record

Trial reportNature cancer2026

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

Paolo Strati, Lori Leslie, Parveen Shiraz, Lihua E Budde, Olalekan O Oluwole, Matthew Ulrickson, Aravind Ramakrishnan, Teresa Zhang, Jennifer Sun, Francesca Milletti and 5 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04002401 (A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04002401 phase2completednot on this map

A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

TypeinterventionalSponsorKite, A Gilead CompanyRan2019 to 2023Enrolled27ConditionsRefractory Large B-cell LymphomaArmsAxicabtagene Ciloleucel, Rituximab, Fludarabine, Cyclophosphamide
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paolo StratiDepartment of Lymphoma and Myeloma and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pstrati@mdanderson.org.ORCID http://orcid.org/0000-0002-7445-1459
Lori LeslieIndolent Lymphoma and CLL Research Programs, John Theurer Cancer Center, Hackensack, NJ, USA.
Parveen ShirazDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6721-0358
Lihua E BuddeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-1464-5494
Olalekan O OluwoleDivision of Hematology Oncology, Vanderbilt University Cancer Center, Nashville, TN, USA.
Matthew UlricksonSection of Hematology, Stem Cell Transplant, and Cellular Therapy, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.ORCID http://orcid.org/0000-0002-1458-7813
Aravind RamakrishnanCenter for Blood Cancers and Oncology, Texas Transplant Physician Group, Austin, TX, USA.
Teresa ZhangKite, a Gilead Company, Santa Monica, CA, USA.
Jennifer SunKite, a Gilead Company, Santa Monica, CA, USA.
Francesca MillettiKite, a Gilead Company, Santa Monica, CA, USA.
Justyna KanskaKite, a Gilead Company, Santa Monica, CA, USA.
Rhine ShenKite, a Gilead Company, Santa Monica, CA, USA.
Frank NeumannKite, a Gilead Company, Santa Monica, CA, USA.
Hairong XuKite, a Gilead Company, Santa Monica, CA, USA.
Krish PatelLymphoma Program and Hematologic Malignancies and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD19-negative relapse occurs in ~30% of persons with relapsed or refractory large B cell lymphoma (LBCL) who respond to axicabtagene ciloleucel (axi-cel; CD19-directed chimeric antigen receptor (CAR) T cell therapy). In this phase 2 single-arm study, 26 participants with chemorefractory LBCL received axi-cel in combination with rituximab. The primary endpoint was investigator-assessed complete response rate; select secondary endpoints included duration of response (DOR), axi-cel pharmacokinetics and safety. The complete response rate was 73%. Median DOR was 26.0 months; 46% of participants had an ongoing response at data cutoff. Peak CAR T cell (normalized by tumor burden) and rituximab area-under-the-curve levels were elevated in participants with complete or ongoing response. Axi-cel plus rituximab treatment led to durable responses with no new safety signals despite persistent B cell aplasia and pharmacokinetics of axi-cel were unaffected, indicating that dual targeting of CD19 and CD20 is a feasible and safe approach to potentially limit antigen escape. ClinicalTrials.gov registration: NCT04002401 .

Indexed as

Antigens, CD19Antineoplastic Combined Chemotherapy ProtocolsBiological ProductsImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseRituximabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedReceptors, Chimeric AntigenTreatment OutcomeAntigens, CD19axicabtagene ciloleucelBiological ProductsCD19 molecule, humanReceptors, Chimeric AntigenRituximab

Identifiers

PMID41492094
PMCPMC12948664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.